According to filings with the U.S. Securities and Exchange Commission, City Therapeutics Inc. has raised $99,500,000.00 in new Series B funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Viking Global Investors, Sofinnova Investments, Casdin Capital, NYBC Ventures.

About City Therapeutics Inc.
City Therapeutics Inc. is a biotechnology company focused on engineering the next generation of RNA interference (RNAi)-based medicines to treat serious diseases by silencing harmful gene expression at the messenger RNA level. Founded by pioneers of the RNAi field, the company emphasizes differentiated science, a strategic and diversified R&D pipeline, sustained momentum, and unrivaled RNAi expertise as the core principles guiding its work. City Therapeutics has built a proprietary platform that designs highly potent, specific, and durable RNAi trigger molecules and pairs them with precision targeting ligands to deliver small interfering RNAs (siRNAs) to a broad range of cell and tissue types, expanding RNAi applications beyond the liver and opening new therapeutic possibilities. Its pipeline includes next-generation RNAi therapy candidates such as CITY-FXI, aimed at preventing dangerous blood clots by targeting the clotting protein Factor XI without increasing bleeding risk, and CITY-RBP4, designed to slow or halt progression of Stargardt disease by reducing expression of the liver-produced protein RBP4 involved in the disease mechanism. Based in Cambridge, Massachusetts, City Therapeutics leverages a leadership team and scientific staff with decades of hands-on RNAi research, development, and regulatory experience to advance what it describes as best-in-class RNAi medicines from concept through clinical development.

To learn more, visit https://www.citytx.com/
Linkedin: https://www.linkedin.com/company/city-therapeutics/

Contact:
Andy Orth, Chief Executive Officer
https://www.linkedin.com/in/andy-orth-87822a6/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.